296 related articles for article (PubMed ID: 29282678)
21. Functional relationship and gene ontology classification of breast cancer biomarkers.
Arciero C; Somiari SB; Shriver CD; Brzeski H; Jordan R; Hu H; Ellsworth DL; Somiari RI
Int J Biol Markers; 2003; 18(4):241-72. PubMed ID: 14756541
[TBL] [Abstract][Full Text] [Related]
22. Molecular signatures in breast cancer.
Lal S; McCart Reed AE; de Luca XM; Simpson PT
Methods; 2017 Dec; 131():135-146. PubMed ID: 28669865
[TBL] [Abstract][Full Text] [Related]
23. Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer.
Maltoni R; Casadio V; Ravaioli S; Foca F; Tumedei MM; Salvi S; Martignano F; Calistri D; Rocca A; Schirone A; Amadori D; Bravaccini S
Oncotarget; 2017 Mar; 8(10):16642-16649. PubMed ID: 28186965
[TBL] [Abstract][Full Text] [Related]
24. CTCs in early breast cancer: A path worth taking.
Maltoni R; Gallerani G; Fici P; Rocca A; Fabbri F
Cancer Lett; 2016 Jul; 376(2):205-10. PubMed ID: 27060205
[TBL] [Abstract][Full Text] [Related]
25. Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.
Welt A; Tewes M; Aktas B; O Hoffmann O; Wiesweg M; Ting S; Reis H; Worm K; Richly H; Hense J; Palmer MR; Lee BH; Wendling J; Kossow J; Scheulen ME; Lehnerdt C; Kohl M; Derks C; Skottky S; Haus U; Schmid KW; Kimmig R; Schuler M; Kasper S
Breast Cancer Res Treat; 2013 Nov; 142(1):81-8. PubMed ID: 24122392
[TBL] [Abstract][Full Text] [Related]
26. The Dawning of Translational Breast Cancer: From Bench to Bedside.
Chen X; Fan S; Song E
Adv Exp Med Biol; 2017; 1026():1-25. PubMed ID: 29282677
[TBL] [Abstract][Full Text] [Related]
27. The ANDROMEDA prospective cohort study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: study protocol.
Giordano L; Gallo F; Petracci E; Chiorino G; Segnan N;
BMC Cancer; 2017 Nov; 17(1):785. PubMed ID: 29166878
[TBL] [Abstract][Full Text] [Related]
28. Multigene prognostic tests in breast cancer: past, present, future.
Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
[TBL] [Abstract][Full Text] [Related]
29. Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer.
Zhu Y; Guo M; Zhang L; Xu T; Wang L; Xu G
Oncol Rep; 2016 Jan; 35(1):454-62. PubMed ID: 26531769
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor cells in breast cancer--current status and perspectives.
Banys-Paluchowski M; Krawczyk N; Meier-Stiegen F; Fehm T
Crit Rev Oncol Hematol; 2016 Jan; 97():22-9. PubMed ID: 26563820
[TBL] [Abstract][Full Text] [Related]
31. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
[TBL] [Abstract][Full Text] [Related]
32. Aberrantly methylated DNA as a biomarker in breast cancer.
Kristiansen S; Jørgensen LM; Guldberg P; Sölétormos G
Int J Biol Markers; 2013; 28(2):141-50. PubMed ID: 23564623
[TBL] [Abstract][Full Text] [Related]
33. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
[TBL] [Abstract][Full Text] [Related]
34. Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients.
Yadav P; Mirza M; Nandi K; Jain SK; Kaza RC; Khurana N; Ray PC; Saxena A
Tumour Biol; 2016 Nov; 37(11):15275-15282. PubMed ID: 27696295
[TBL] [Abstract][Full Text] [Related]
35. Serum proteome profiling of primary breast cancer indicates a specific biomarker profile.
Böhm D; Keller K; Wehrwein N; Lebrecht A; Schmidt M; Kölbl H; Grus FH
Oncol Rep; 2011 Nov; 26(5):1051-6. PubMed ID: 21837365
[TBL] [Abstract][Full Text] [Related]
36. BARD1, a possible biomarker for breast and ovarian cancer.
Irminger-Finger I
Gynecol Oncol; 2010 May; 117(2):211-5. PubMed ID: 19959210
[TBL] [Abstract][Full Text] [Related]
37. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.
Kazarian A; Blyuss O; Metodieva G; Gentry-Maharaj A; Ryan A; Kiseleva EM; Prytomanova OM; Jacobs IJ; Widschwendter M; Menon U; Timms JF
Br J Cancer; 2017 Feb; 116(4):501-508. PubMed ID: 28081538
[TBL] [Abstract][Full Text] [Related]
38. Circulating Plasma Tumor DNA.
Parsons HA; Beaver JA; Park BH
Adv Exp Med Biol; 2016; 882():259-76. PubMed ID: 26987539
[TBL] [Abstract][Full Text] [Related]
39. Pilot Study of Serum MicroRNA-21 as a Diagnostic and Prognostic Biomarker in Egyptian Breast Cancer Patients.
Toraih EA; Mohammed EA; Farrag S; Ramsis N; Hosny S
Mol Diagn Ther; 2015 Jun; 19(3):179-90. PubMed ID: 26063582
[TBL] [Abstract][Full Text] [Related]
40. Biomolecular features of clinical relevance in breast cancer.
Daidone MG; Paradiso A; Gion M; Harbeck N; Sweep F; Schmitt M
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S3-14. PubMed ID: 15095022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
